Klotho Deficiency Causes Heart Aging via Impairing the Nrf2-GR Pathway
- 17 December 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 128 (4), 492-507
- https://doi.org/10.1161/CIRCRESAHA.120.317348
Abstract
Rationale: Cardiac aging is an important contributing factor for heart failure, which affects a large population but remains poorly understood. Objective: The purpose of this study is to investigate whether Klotho plays a role in cardiac aging. Methods and Results: Heart function declined in old mice (24 months), as evidenced by decreases in fractional shortening, ejection fraction, and cardiac output. Heart size and weight, cardiomyocyte size, and cardiac fibrosis were increased in old mice, indicating that aging causes cardiac hypertrophy and remodeling. Circulating Klotho levels were dramatically decreased in old mice, which prompted us to investigate whether the Klotho decline may cause heart aging. We found that Klotho gene mutation (KL-/-) largely decreased serum klotho levels and impaired heart function. Interestingly, supplement of exogenous secreted Klotho prevented heart failure, hypertrophy, and remodeling in both old mice and KL (-/-) mice. Secreted Klotho treatment inhibited excessive cardiac oxidative stress, senescence and apoptosis in old mice and KL (-/-) mice. Serum phosphate levels in KL (-/-) mice were kept in the normal range, suggesting that Klotho deficiency-induced heart aging is independent of phosphate metabolism. Mechanistically, Klotho deficiency suppressed GR (glutathione reductase) expression and activity in the heart via inhibition of transcription factor Nrf2 (nuclear factor-erythroid 2 p45-related factor 2). Furthermore, cardiac-specific overexpression of GR prevented excessive oxidative stress, apoptosis, and heart failure in both old and KL (-/-) mice. Conclusions: Klotho deficiency causes cardiac aging via impairing the Nrf2-GR pathway. Supplement of exogenous secreted Klotho represents a promising therapeutic strategy for aging-associated cardiomyopathy and heart failure.Keywords
Funding Information
- HHS | NIH | National Institute on Aging (AG062375)
- HHS | NIH | National Institute on Aging (AG049780)
- HHS | NIH | National Heart, Lung, and Blood Institute (HL154147)
- HHS | NIH | National Heart, Lung, and Blood Institute (HL122166)
This publication has 66 references indexed in Scilit:
- Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heartNature Communications, 2012
- Cellular senescence and tumor suppressor gene p16International Journal of Cancer, 2011
- The Aging Heart and Post-Infarction Left Ventricular RemodelingJournal of the American College of Cardiology, 2011
- Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formationProceedings of the National Academy of Sciences of the United States of America, 2009
- The FGF23–Klotho axis: endocrine regulation of phosphate homeostasisNature Reviews Endocrinology, 2009
- Cardiac Aging in Mice and Humans: The Role of Mitochondrial Oxidative StressTrends in Cardiovascular Medicine, 2009
- Current understanding of klothoAgeing Research Reviews, 2009
- Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stressFree Radical Biology & Medicine, 2008
- Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17Proceedings of the National Academy of Sciences of the United States of America, 2007
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006